- Home
- PMVP vs DTIL Comparison
PMVP vs DTIL Comparison
Compare PMVP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- DTIL
- Stock Information
- Founded
- PMVP 2013
- DTIL 2006
- Country
- PMVP United States
- DTIL United States
- Employees
- PMVP N/A
- DTIL N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- DTIL Health Care
- Exchange
- PMVP Nasdaq
- DTIL Nasdaq
- Market Cap
- PMVP 55.1M
- DTIL 51.6M
- IPO Year
- PMVP 2020
- DTIL 2019
- Fundamental
- Price
- PMVP $1.09
- DTIL $4.79
- Analyst Decision
- PMVP Strong Buy
- DTIL Strong Buy
- Analyst Count
- PMVP 1
- DTIL 2
- Target Price
- PMVP $5.00
- DTIL $47.00
- AVG Volume (30 Days)
- PMVP 362.7K
- DTIL 85.2K
- Earning Date
- PMVP 08-07-2025
- DTIL 07-31-2025
- Dividend Yield
- PMVP N/A
- DTIL N/A
- EPS Growth
- PMVP N/A
- DTIL N/A
- EPS
- PMVP N/A
- DTIL N/A
- Revenue
- PMVP N/A
- DTIL $51,141,000.00
- Revenue This Year
- PMVP N/A
- DTIL N/A
- Revenue Next Year
- PMVP N/A
- DTIL $30.20
- P/E Ratio
- PMVP N/A
- DTIL N/A
- Revenue Growth
- PMVP N/A
- DTIL N/A
- 52 Week Low
- PMVP $0.81
- DTIL $3.61
- 52 Week High
- PMVP $1.82
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- PMVP 61.16
- DTIL 44.86
- Support Level
- PMVP $1.01
- DTIL $4.20
- Resistance Level
- PMVP $1.12
- DTIL $5.29
- Average True Range (ATR)
- PMVP 0.07
- DTIL 0.36
- MACD
- PMVP 0.01
- DTIL -0.03
- Stochastic Oscillator
- PMVP 64.00
- DTIL 36.88
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.